Search Results

Follow along as BioSpace tracks job cuts and restructuring initiatives.

Eli Lilly sauntered into the American Diabetes Association meeting with a commanding lead in the metabolic space and put down more evidence for its pipeline, including new pill Foundayo and next-gen asset retatrutide, in new indications.

Analysts and investors were unimpressed by Phase 2 data posted in the spring showing that an amylin analog developed by Roche and partner Zealand Pharma elicited 9% weight loss, less than Eli Lilly’s rival candidate. Executives from both companies told BioSpace that premium weight loss is not the point of petrelintide.

Join patient access professionals and advocates for the National Chronic Disease Day Leadership Luncheon on July 10. Good Days, the founder of Chronic Disease Day, will convene senior biotech executives, healthcare leaders, patient advocates, and policymakers at MassBio for a focused discussion on improving access to care, advancing innovation, and strengthening collaboration across the healthcare ecosystem. Seating limited to 80 attendees.

The American Diabetes Association’s annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door.

The FDA must provide consistent and predictable regulatory frameworks if the U.S. is to maintain its leadership in gene therapy, one of the most consequential therapeutic fields of our generation.